The study analyzed that the uveitis therapeutics pipeline comprises 33 drug
candidates in different stages of development. Uveitis is a type of
inflammatory disease that causes swelling and destroys eye tissues. Occurrence
of this disease can result in slight reduction of vision or lead to complete
vision loss. Uveitis occurs when the middle layer of the eyeball gets inflamed
(red and swollen). This layer, known as the uvea, has many blood vessels that
nourish the eye. Uveitis can damage vital eye tissue, even resulting in
permanent vision loss.
Explore Report Description at: https://www.psmarketresearch.com/market-analysis/uveitis-therapeutics-pipeline-analysis
pSivida Corp. is using durasert technology platform for the development
of Medidur for the treatment of uveitis. This technology platform is used to
provide sustained, localized delivery of drugs to the back of the eye. Durasert
products are developed with a drug core surrounded with one or more polymer
layers, the permeability of those layers and other aspects of the design of the
product, controls the rate and duration of the drug release. However, changing
the elements of the design, can help in altering both the rate and duration of
release to meet different therapeutic needs. The later generation durasert
products and product candidates are injected at the target site, while early
generations were surgically implanted.
Many companies are involved in the development of drugs for the uveitis
therapeutics pipeline, with their products in different phases.
Explore Report Sample
at: https://www.psmarketresearch.com/market-analysis/uveitis-therapeutics-pipeline-analysis/report-sample
Some of the key players developing drugs for the treatment of uveitis
include Aldeyra Therapeutics, Inc., EyeGate Pharmaceuticals, Inc., pSivida
Corp. and others.
No comments:
Post a Comment